At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Sym023drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
In Brief
A Phase 1 clinical trial evaluating Sym023 for Metastatic Cancer and 2 related conditions. Completed, enrolled 24 participants across 4 sites in 2 countries.
Detailed Summary
This was the first study to test Sym023 in humans. The primary purpose of this study was to see if Sym023 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Cancer, Solid Tumor, Lymphoma
CountriesCanada, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartMay 2018
Primary CompletionJun 2020
TodayJul 2026
First PostedApr 5, 2018
Enrollment StartMay 24, 2018
Primary CompletionJun 3, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.2 years ago
Interventions
Sym023drug
Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.